💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Methylprednisolone

CHEMBL650 Phase 4 承認済み Small molecule
Half-Life
18-36 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
374.5 g/mol
LogP
1.9
Phase
4

A corticosteroid used to treat a wide range of inflammatory and autoimmune conditions, including allergic reactions, asthma flares, rheumatoid arthritis, and multiple sclerosis relapses. It is available in oral, injectable, and topical forms.

分子量

374.4710 g/mol

LogP

1.90

TPSA

94.80 Ų

リピンスキーの五則

適合

治療領域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Glaucoma Cardiovascular Disease Age-Related Macular Degeneration Respiratory Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Asthma Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Psoriasis Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Obesity Lymphoma Type 2 Diabetes Hypertension Breast Cancer Atopic Dermatitis Gout Chronic Pain HIV/AIDS Tuberculosis Heart Failure Prostate Cancer Colorectal Cancer Leukemia

薬物分類

H — H - Systemic Hormonal Preparations, Excluding Sex Hormones and Insulins

作用機序

Intermediate-acting synthetic glucocorticoid.

Pharmacokinetics (PK)

Half-Life 18-36 hours

Pharmacodynamics (PD)

機序

Intermediate-acting synthetic glucocorticoid.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12

                

                

                
                

                    
InChI

                    
InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H30O5

                    

                    
                    

                        
HBD / HBA

                        
3 / 5

                    

                    
                    

                        
回転可能結合数

                        
2

                    

                    
                    
                    

                        
重原子数

                        
27

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            PPARG (Peroxisome Proliferator-Activated Receptor Gamma)
                            Agonist
                        

                        
                        Primary Target
                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Moderate


                            
                                Methylprednisolone + Diltiazem
                            
                        

                        
                        
Diltiazem inhibits CYP3A4-mediated methylprednisolone metabolism, increasing methylprednisolone exposure and the risk of steroid side effects including immunosuppression, hyperglycaemia, and hypertension.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Methylprednisolone + Fluconazole
                            
                        

                        
                        
Fluconazole inhibits CYP3A4-mediated metabolism of methylprednisolone, increasing its plasma levels and prolonging corticosteroid effects, raising the risk of Cushingoid features.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Methylprednisolone + Cyclosporine
                            
                        

                        
                        
Methylprednisolone inhibits CYP3A4-mediated cyclosporine metabolism, raising cyclosporine levels; conversely, cyclosporine may increase methylprednisolone exposure — a bidirectional pharmacokinetic interaction.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
A corticosteroid used to treat a wide range of inflammatory and autoimmune conditions, including allergic reactions, asthma flares, rheumatoid arthritis, and multiple sclerosis relapses. It is available in oral, injectable, and topical forms.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Intermediate-acting synthetic glucocorticoid.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Methylprednisolone: Half-life: 18-36 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Methylprednisolone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Levothyroxine
                            Small molecule
                        
                        
                        
                            Prednisone
                            Small molecule
                        
                        
                        
                            Dexamethasone
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL650.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 6741.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.